Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $21.2 million.

  • Orchestra BioMed Holdings' Operating Expenses rose 2218.82% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.1 million, marking a year-over-year increase of 2438.81%. This contributed to the annual value of $66.9 million for FY2024, which is 2335.35% up from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Operating Expenses is $21.2 million, which was up 2218.82% from $20.2 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Operating Expenses high stood at $21.2 million for Q3 2025, and its period low was $6.0 million during Q1 2022.
  • For the 4-year period, Orchestra BioMed Holdings' Operating Expenses averaged around $14.6 million, with its median value being $14.9 million (2023).
  • In the last 5 years, Orchestra BioMed Holdings' Operating Expenses skyrocketed by 11202.87% in 2023 and then surged by 1432.22% in 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' Operating Expenses (Quarter) stood at $10.9 million in 2022, then grew by 16.58% to $12.7 million in 2023, then skyrocketed by 32.86% to $16.9 million in 2024, then grew by 25.07% to $21.2 million in 2025.
  • Its Operating Expenses was $21.2 million in Q3 2025, compared to $20.2 million in Q2 2025 and $19.8 million in Q1 2025.